Overview
MASLD (Metabolic Associated Steato-Lipodystrophy Disease), often encompassing NASH (Nonalcoholic Steatohepatitis) with advanced fibrosis stages (F2-F3), involves metabolic dysfunction leading to liver damage and increased risk of complications such as cirrhosis and hepatocellular carcinoma 1.Diagnosis
Fibrosis staging using biopsy or non-invasive methods (e.g., elastography) to assess F2 or F3 fibrosis 1.
Assessment of metabolic parameters including liver function tests, lipid profiles, and markers of inflammation 1.
Identification of compensated cirrhosis (CC) and decompensated cirrhosis (DC) through clinical symptoms and laboratory findings 1.Management
First-line Treatment: Resmetirom for patients with F2 or F3 fibrosis to improve fibrosis and metabolic dysfunction 1.
Adjunctive Measures: Lifestyle modifications including diet and exercise, weight management, and control of comorbidities like diabetes and dyslipidemia 1.Special Populations
No specific data provided in the abstracts regarding pregnancy, pediatrics, elderly, or comorbidities in the context of Resmetirom treatment for MASLD 1.Key Recommendations
Initiate Resmetirom treatment in adults with MASLD and F2 or F3 fibrosis to potentially reduce progression to advanced fibrosis and related complications (Evidence: Strong) 1.
Monitor patients for long-term outcomes including compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, and mortality (Evidence: Moderate) 1.
Consider lifestyle interventions alongside pharmacological treatment to manage metabolic risk factors in MASLD patients (Evidence: Expert opinion) 1.References
1 Pennisi G, Di Maria G, Enea M, Vaccaro M, Celsa C, Antonucci M et al.. A Markov Model Unveiling the Impact of Resmetirom on the Natural History of MASLD Patients: A Sistematic Review and Meta-Analysis. Liver international : official journal of the International Association for the Study of the Liver 2025. link